|Awarded On||February 19, 2020|
|Title||High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Konstantin Sokolov|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Immunotherapy is emerging as an exciting new approach to cancer therapy that often has fewer side effects compared to traditional combinations of radiation, chemotherapy, and surgery. MD Anderson is a leader in NK cell therapy development with more than a dozen active clinical trials including the first in human, FDA-approved, Phase-I clinical trial (NCT02271711) for children with recurrent brain tumors. Unfortunately, little is known about the biodistribution of NK cells after administration. Imaging strategies that allow visualization of their distribution could provide invaluable new information to help guide the development of optimized cancer therapies. 19F perfluorocarbon (PFC)-b...